NEW YORK (GenomeWeb) – EKF Diagnostics recently announced that its board of directors has initiated a strategic review, to be led by an independent committee of non-executive directors consisting of Adam Reynolds, David Toohey, Doris Ann Williams, and chaired by Kevin Wilson.

The review was initiated at the suggestion of shareholders and is being done to explore all strategic options available to ensure shareholder value, a spokesperson for the firm told GenomeWeb in an email.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.